ISPOR Europe 2022

We are looking forward to meeting you at ISPOR 2022.

Vienna, Austria | 6 – 9 November

PharmaLex Market Access Team welcomes all delegates, partners and clients to join us at ISPOR 2022 at Booth 108 in Hall 3, to discuss the latest trends within the industry and learn more about how PharmaLex can bring your projects up to success.
Our teams from Spain and Italy will present 10 posters covering key challenges on regional and European level.

Find more details in the links below:


High Doses of Treprostinil Could Entail Lower Hospitalization Costs in Patients With Pulmonary Arterial Hypertension in Nine European Countries

Cost-Effectiveness Analysis of Cemiplimab for Patients with Advanced Non-Small Cell Lung Carcinoma in Spain

A Cost-Utility Analysis of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, a Rare Disease, in Spain

The Economic Impact of Empagliflozin in Adult Patients With Chronic Heart Failure in Spain

Cost of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) in Spain: A Delphi Approach



Critical Analysis on Time-to-Reimbursement of Rare Disease Drugs: The Italian Case (AIFA Commissions 2018-2022)

Prevalence As a Driver of Treatment Cost for Drugs in the Rare Disease Field in Italy

Progression Free Survival and Duration of Treatment as a Proxy of Disease Severity: Use of These Variables to Determine Price Benchmarks

Analysis of the Time Spent by AIFA Committees for the Assessment of New Drugs: Impact of the Application of Managed Entry Agreements

Retrospective Analysis of the Negotiation in AIFA for New Therapeutic Indications

Related Events

Scroll to Top